|
1
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality, and prevalence across five
continents: Defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gupta S, Kong W, Peng Y, Miao Q and
Mackillop WJ: Temporal trends in the incidence and survival of
cancers of the upper aerodigestive tract in Ontario and the United
States. Int J Cancer. 125:2159–2165. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ferlito A, Shaha AR, Silver CE, Rinaldo A
and Mondin V: Incidence and sites of distant metastases from head
and neck cancer. ORL J Otorhinolaryngol Relat Spec. 63:202–207.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ozdek A, Sarac S, Akyol MU, Unal OF and
Sungur A: Histopathological predictors of occult lymph node
metastases in supraglottic squamous cell carcinomas. Eur Arch
Otorhinolaryngol. 257:389–392. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell
lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Reck M, Rodríguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: KEYNOTE-024 Investigators: Pembrolizumab versus
chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl
J Med. 375:1823–1833. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Seiwert TY, Zuo Z, Keck MK, Khattri A,
Pedamallu CS, Stricker T, Brown C, Pugh TJ, Stojanov P, Cho J, et
al: Integrative and comparative genomic analysis of HPV-positive
and HPV-negative head and neck squamous cell carcinomas. Clin
Cancer Res. 21:632–641. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Swiecicki PL, Zhao L, Belile E, Sacco AG,
Chepeha DB, Dobrosotskaya I, Spector M, Shuman A, Malloy K, Moyer
J, et al: A phase II study evaluating axitinib in patients with
unresectable, recurrent or metastatic head and neck cancer. Invest
New Drugs. 33:1248–1256. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sweeny L, Zimmermann TM, Liu Z and
Rosenthal EL: Evaluation of tyrosine receptor kinases in the
interactions of head and neck squamous cell carcinoma cells and
fibroblasts. Oral Oncol. 48:1242–1249. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Quail DF and Joyce JA: Microenvironmental
regulation of tumor progression and metastasis. Nat Med.
19:1423–1437. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Balkwill FR, Capasso M and Hagemann T: The
tumor microenvironment at a glance. J Cell Sci. 125:5591–5596.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Freier K, Schwaenen C, Sticht C,
Flechtenmacher C, Mühling J, Hofele C, Radlwimmer B, Lichter P and
Joos S: Recurrent FGFR1 amplification and high FGFR1 protein
expression in oral squamous cell carcinoma (OSCC). Oral Oncol.
43:60–66. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Henson BJ and Gollin SM: Overexpression of
KLF13 and FGFR3 in oral cancer cells. Cytogenet Genome Res.
128:192–198. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wheeler SE, Shi H, Lin F, Dasari S,
Bednash J, Thorne S, Watkins S, Joshi R and Thomas SM: Enhancement
of head and neck squamous cell carcinoma proliferation, invasion,
and metastasis by tumor-associated fibroblasts in preclinical
models. Head Neck. 36:385–392. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ornitz DM and Marie PJ: Fibroblast growth
factor signaling in skeletal development and disease. Genes Dev.
29:1463–1486. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhao Y and Adjei AA: Targeting
angiogenesis in cancer therapy: moving beyond vascular endothelial
growth factor. Oncologist. 20:660–673. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schultz-Hector S and Haghayegh S:
Beta-fibroblast growth factor expression in human and murine
squamous cell carcinomas and its relationship to regional
endothelial cell proliferation. Cancer Res. 53:1444–1449.
1993.PubMed/NCBI
|
|
20
|
Koole K, Brunen D, van Kempen PM, Noorlag
R, de Bree R, Lieftink C, van Es RJ, Bernards R and Willems SM:
FGFR1 is a potential prognostic biomarker and therapeutic target in
head and neck squamous cell carcinoma. Clin Cancer Res.
22:3884–3893. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Harris BH, Barberis A, West CM and Buffa
FM: Gene expression signatures as biomarkers of tumour hypoxia.
Clin Oncol (R Coll Radiol). 27:547–560. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hsu HW, Wall NR, Hsueh CT, Kim S, Ferris
RL, Chen CS and Mirshahidi S: Combination antiangiogenic therapy
and radiation in head and neck cancers. Oral Oncol. 50:19–26. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mărgăritescu C, Pirici D, Stîngă A,
Simionescu C, Raica M, Mogoantă L, Stepan A and Ribatti D: VEGF
expression and angiogenesis in oral squamous cell carcinoma: An
immunohistochemical and morphometric study. Clin Exp Med.
10:209–214. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Denhart BC, Guidi AJ, Tognazzi K, Dvorak
HF and Brown LF: Vascular permeability factor/vascular endothelial
growth factor and its receptors in oral and laryngeal squamous cell
carcinoma and dysplasia. Lab Invest. 77:659–664. 1997.PubMed/NCBI
|
|
25
|
Tong M, Lloyd B, Pei P and Mallery SR:
Human head and neck squamous cell carcinoma cells are both targets
and effectors for the angiogenic cytokine, VEGF. J Cell Biochem.
105:1202–1210. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gao J, Aksoy BA, Dogrusoz U, Dresdner G,
Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al:
Integrative analysis of complex cancer genomics and clinical
profiles using the cBioPortal. Sci Signal. 6:pl12013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Brands RC, Herbst F, Hartmann S, Seher A,
Linz C, Kübler AC and Müller-Richter UD: Cytotoxic effects of
SMAC-mimetic compound LCL161 in head and neck cancer cell lines.
Clin Oral Investig. 20:2325–2332. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kramer B, Hock C, Birk R, Sauter A, Stuck
BA, Hörmann K, Schultz JD and Aderhold C: Targeted therapies in
HPV-positive and -negative HNSCC - alteration of EGFR and VEGFR-2
expression in vitro. Anticancer Res. 36:2799–2807. 2016.PubMed/NCBI
|
|
31
|
Pentheroudakis G, Angouridakis N, Wirtz R,
Nikolaou A, Kalogeras KT, Pavlidis N and Fountzilas G:
Transcriptional activity of human epidermal growth factor receptor
family and angiogenesis effectors in locoregionally recurrent head
and neck squamous cell carcinoma and correlation with patient
outcome. J Oncol. 2009:8541272009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ipenburg NA, Koole K, Liem KS, van Kempen
PM, Koole R, van Diest PJ, van Es RJ and Willems SM: Fibroblast
growth factor receptor family members as prognostic biomarkers in
head and neck squamous cell carcinoma: A Systematic Review. Target
Oncol. 11:17–27. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hamberg P, Verweij J and Sleijfer S:
(Pre-)clinical pharmacology and activity of pazopanib, a novel
multikinase angiogenesis inhibitor. Oncologist. 15:539–547. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cohen EE, Davis DW, Karrison TG, Seiwert
TY, Wong SJ, Nattam S, Kozloff MF, Clark JI, Yan DH, Liu W, et al:
Erlotinib and bevacizumab in patients with recurrent or metastatic
squamous-cell carcinoma of the head and neck: A phase I/II study.
Lancet Oncol. 10:247–257. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cenik B Kutluk, Ostapoff KT, Gerber DE and
Brekken RA: BIBF 1120 (nintedanib), a triple angiokinase inhibitor,
induces hypoxia but not EMT and blocks progression of preclinical
models of lung and pancreatic cancer. Mol Cancer Ther. 12:992–1001.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kudo K, Arao T, Tanaka K, Nagai T, Furuta
K, Sakai K, Kaneda H, Matsumoto K, Tamura D, Aomatsu K, et al:
Antitumor activity of BIBF 1120, a triple angiokinase inhibitor,
and use of VEGFR2+pTyr+ peripheral blood
leukocytes as a pharmacodynamic biomarker in vivo. Clin Cancer Res.
17:1373–1381. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Konecny GE, Finkler N, Garcia AA, Lorusso
D, Lee PS, Rocconi RP, Fong PC, Squires M, Mishra K, Upalawanna A,
et al: Second-line dovitinib (TKI258) in patients with
FGFR2-mutated or FGFR2-non-mutated advanced or metastatic
endometrial cancer: A non-randomised, open-label, two-group,
two-stage, phase 2 study. Lancet Oncol. 16:686–694. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lee SH, de Lopes Menezes D, Vora J, Harris
A, Ye H, Nordahl L, Garrett E, Samara E, Aukerman SL, Gelb AB, et
al: In vivo target modulation and biological activity of CHIR-258,
a multitargeted growth factor receptor kinase inhibitor, in colon
cancer models. Clin Cancer Res. 11:3633–3641. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ku X: Development and application of small
molecule probes for kinase affinity purification and quantitative
chemical proteomics (Thesis)Fakultät Wissenschaftszentrum
Weihenstephan für Ernährung. Landnutzung und Umwelt Technische
Universität München; München: pp. 1292014, http://docplayer.net/6560816-Technische-universitat-munchen-lehrstuhl-fur-proteomik-und-bioanalytik-xin-ki.html
|
|
40
|
Canter D, Kutikov A, Golovine K, Makhov P,
Simhan J, Uzzo RG and Kolenko VM: Are all multi-targeted tyrosine
kinase inhibitors created equal? An in vitro study of sunitinib and
pazopanib in renal cell carcinoma cell lines. Can J Urol.
18:5819–5825. 2011.PubMed/NCBI
|
|
41
|
Kim ST, Jang HL, Lee SJ, Lee J, Choi YL,
Kim KM, Cho J, Park SH, Park YS, Lim HY, et al: Pazopanib, a novel
multitargeted kinase inhibitor, shows potent in vitro antitumor
activity in gastric cancer cell lines with FGFR2 amplification. Mol
Cancer Ther. 13:2527–2536. 2014. View Article : Google Scholar : PubMed/NCBI
|
